Efficiency of use of selective dopamine (D2) receptor agonists for the prevention of ovarian hyperstimulation syndrome

Ashkharua T.A.; Krasnopol'skaia K.V.; Manannikova T.N.

doi:https://doi.org/

Ashkharua T.A.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii

Krasnopol'skaia K.V.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii;
kafedra akusherstva i ginekologii FUV MONIKI im. M.F. Vladimirskogo

SPIN RSCI: 1252-3811
Scopus AuthorID: 57370972700

Manannikova T.N.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii

Efficiency of use of selective dopamine (D2) receptor agonists for the prevention of ovarian hyperstimulation syndrome

Authors:

Ashkharua T.A., Krasnopol'skaia K.V., Manannikova T.N.

More about the authors

Journal: Russian Bulletin of Obstetrician-Gynecologist. 2011;11(4): 67‑72

Read: 1278 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Ashkharua TA, Krasnopol'skaia KV, Manannikova TN. Efficiency of use of selective dopamine (D2) receptor agonists for the prevention of ovarian hyperstimulation syndrome. Russian Bulletin of Obstetrician-Gynecologist. 2011;11(4):67‑72. (In Russ.)

Подписка 2026 Российский вестник акушера-гинеколога (Russian Bulletin of Obstetrician-Gynecologist)

Использование инфографики авторами научных работ

Close metadata

Abstract:

The paper presents the results of use of stimulated in-vitro fertilization cycles in 45 patients with more than 20 growing follicles, who received human chorionic gonadotropin (hCG), 5000 IU, as an ovulation trigger and dopamine (D2) receptor agonists (cabergoline) for the prevention of ovarian hyperstimulation syndrome (OHSS); in 94 patients with less than or equal to 20 growing follicles, who took hCG, 10 000 IU, as an ovarian trigger, and in 47 patients with more than 20 growing follicles who used hCG, 5000 IU, as an ovarian trigger. Cabergoline was demonstrated to be able to significantly reduce the incidence of early OHSS in patients with a verified hyperergic response of the follicular apparatus to gonadotropins without its negative effect on the probability of the occurrence of pregnancy and its course in the first trimester.

Keywords:

dopamine (D2) receptor agonists

cabergoline

ovarian hyperstimulation syndrome

Authors:

Ashkharua T.A.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii

Krasnopol'skaia K.V.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii;
kafedra akusherstva i ginekologii FUV MONIKI im. M.F. Vladimirskogo

SPIN RSCI: 1252-3811
Scopus AuthorID: 57370972700

Manannikova T.N.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii

Close metadata

References:

Kazaryan L.M. Optimizatsiya metoda ekstrakorporal'nogo oplodotvoreniya i perenosa embrionov putem ispol'zovaniya programmy kriokonservatsii embrionov: Avtoref. dis. … kand. med. nauk. M 2005;24.
Korneeva I.E. Sindrom giperstimulyatsii yaichnikov. V kn.: Besplodnyi brak. Pod red. V.I. Kulakova. M: GEOTAR-Media 2006;449-496.
Kornilov N.V. Trigger final'nogo sozrevaniya follikulov v programmakh EKO: Agonisty GnRG dlya triggera final'nogo sozrevaniya follikulov. Probl reprod 2002;8:3:26-45.
Nazarenko T.A. Stimulyatsiya funktsii yaichnikov. M: MEDpress-inform 2009;272.
Saroyan T.T. Osobennosti techeniya beremennosti u zhenshchin s tyazheloi formoi sindroma giperstimulyatsii yaichnikov: Avtoref. dis. … kand. med. nauk. M 2009;24.
Safronova E.V., Pastukhova E.A., Pekarev V.A. Ispol'zovanie coasting dlya profilaktiki sindroma giperstimulyatsii yaichnikov. Probl reprod 2006;12:2:21-24.
Taskina O.A. Sovremennye predstavleniya i metody profilaktiki sindroma giperstimulyatsii yaichnikov. Probl reprod 2007;13:5:42-48.
Tomazevich T., Meden-Vrtovek Kh. Rannyaya aspiratsiya follikulov predotvrashchaet razvitie sindroma giperstimulyatsii tyazheloi stepeni. Probl reprod 2004;10:1:28-31.
Shcherbakova L.N. Sindrom giperstimulyatsii yaichnikov v programme ekstrakorporal'nogo oplodotvoreniya: Klinicheskoe techenie i reproduktivnye poteri: Avtoref. dis. … kand. med. nauk. M 2010;24.
Aboulghar M.A., Mansour R.T. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update 2003;9:3:275-289.
Aflatoonian A., Ghandi S., Soleimani M. et al. Comparison of coasting with carbegolin administration for prevention of severe OHSS in ART cycles. Hum Reprod 2007;22:Suppl 1:Abstract Book:131-331.
Alvarez C., Bosch E., Melo M.A.B. The dopamine agonist Carbergoline prevents moderat-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients. Hum Reprod 2006;21:Suppl 1:Abstract Book:O-249:96.
Alvarez C., Marti L., Novella E. et al. Dopamine agonist cabergoline reduced hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endicrinol Metab 2007;92:2882-2884.
Alvarez C., Alonso-Muriel I., Garcia G. et al. Implantation is apparently unaffected by dopamine agonist cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 2007;22:3210-3214.
Busso C., Fernandez-Sanchez M., Garsia-Velasco J.A. et al. Quinagolide is effective in preventing moderate/severe early OHSS in IVF patients: a randomized, double-blind, placebo-controlled trial. Hum Reprod 2008;23:Suppl 1:Abstract Book:O-149:60.
Carizza C., Abdelmassih V., Melati L. et al. Cabergoline prevents early but not late onset ovarian hiperstimulation syndrome (OHSS). Hum Reprod 2007;22:Suppl 1:Abstract Book:O-176:71.
Carizza C., Abdelmassih V., Ravizzini P.C. Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg/ml on the day of the hCG. Hum Reprod 2008;23:Suppl 1:Abstract Book:P-350:141-142.
Garsia-Velasco J.A., Isaza V., Quea G., Pellicer A. Coasting for prevention of ovarian hyperstimulation syndrome: much ado about nothing? Fertil Steril 2006;85:547-554.
Humaidan P., Papanikolaou E. Tarlatzis GnRHa to trigger final oocyte maturation: a time to reconsider. Hum Reprod 2009;24:10:2389-2397.
Nargund G., Hutchison L., Scaramuzzi R., Campbell S. Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cycles. Reprod BioMed Online 2007;14:6:682-685.
Raziel A., Friedler S., Schachter M. et al. Increased early pregnancy loss in IVF patients with severe ovarian hyperstimulation syndrome. Hum Reprod 2002;17:1:107-110.
Shaltout A., Shohayeb A., Eid M., Abbas S. Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Hum Reprod 2009;24:Suppl 1:Abstract Book:O-154:61-62.
Verdu Merino V., Gonzales-Villafanez V., Alarcon M. et al. Use of cabergolin for ovarian hyperstimulation syndrome prevention. Hum Reprod 2007;22:Suppl 1:Abstract Book:P-373:146.
Youssef M., Van Wely M., Abdellah M. et al. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum Reprod 2010;25:Suppl 1:Abstract Book:O-150:58.